Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 12;7:11. doi: 10.1038/s41523-021-00222-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Forest plots of PFS, OS, DoCB and CBR. ^*Fixed effect for trial was fitted in all models. ^†Fixed-effect model was fitted to the SERD 250 mg, SERD 500 mg and all data; random effects for trial were included in the models for AI. b Projected probability of PFS, OS and DoCB. Median (95% CI) PFS/OS/DoCB in months. AI aromatase inhibitor, CBR clinical benefit rate, DoCB duration of clinical benefit, HR hazard ratio, n number of patients, non-VM non-visceral metastases, PFS progression-free survival, OR odds ratio, OS overall survival, SERD selective estrogen receptor degrader, SERM selective estrogen receptor modulator, VLM visceral liver metastases, VM visceral metastases, VnLM visceral non-liver metastases. Statistics for full models:PFS: AI: p < 0·001, heterogeneity test p = 0·13; SERD (250 mg): p < 0·001, heterogeneity test p = 0·08; SERD (500 mg): p = 0·048, heterogeneity test p = 0·83; All: p < 0·001, heterogeneity test p = 0·17. OS: AI: p = 0·036, heterogeneity test p = 0·35; SERD (250 mg): p < 0·001, heterogeneity test p = 0·95; SERD (500 mg): p = 0·161, heterogeneity test p = 1·00; All: p < 0·001, heterogeneity test p = 0·86. DoCB: AI: p = 0·007, heterogeneity test p = 0·40; SERD (250 mg): p = 0·023, heterogeneity test p = 0·08; SERD (500 mg): p = 0·720, heterogeneity test p = 0·31; All: p < 0·001, heterogeneity test p = 0·19. CBR: AI: p = 0·454, heterogeneity test p = 0·87; SERD (250 mg): p = 0·503, heterogeneity test p = 0·03; SERD (500 mg): p = 0·021, heterogeneity test p = 0·52; All: p = 0·109, heterogeneity test p = 0·10.